Latest Insider Transactions at Day One Biopharmaceuticals, Inc. (DAWN)
This section provides a real-time view of insider transactions for Day One Biopharmaceuticals, Inc. (DAWN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Day One Biopharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Day One Biopharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 06
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
97,692
-1.5%
|
$1,758,456
$18.05 P/Share
|
|
Dec 03
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,517
-0.19%
|
$225,306
$18.47 P/Share
|
|
Dec 01
2021
|
Samuel C. Blackman HEAD OF R&D |
SELL
Open market or private sale
|
Direct |
10,000
-0.24%
|
$170,000
$17.56 P/Share
|
|
Nov 24
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
801,138
-10.0%
|
-
|
|
Nov 24
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
57,224
+0.87%
|
-
|
|
Oct 22
2021
|
Samuel C. Blackman HEAD OF R&D |
BUY
Bona fide gift
|
Indirect |
1,000,000
+50.0%
|
-
|
|
Oct 22
2021
|
Samuel C. Blackman HEAD OF R&D |
SELL
Bona fide gift
|
Direct |
1,000,000
-41.9%
|
-
|
|
Jun 01
2021
|
Ai Day1 LLC |
BUY
Open market or private purchase
|
Direct |
875,000
+8.53%
|
$14,000,000
$16.0 P/Share
|
|
Jun 01
2021
|
Ai Day1 LLC |
BUY
Conversion of derivative security
|
Direct |
8,502,776
+50.0%
|
-
|
|
Jun 01
2021
|
Canaan Xi L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
13,000
+0.12%
|
$208,000
$16.0 P/Share
|
|
Jun 01
2021
|
Canaan Xi L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
7,476,776
+21.15%
|
-
|
|
Jun 01
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+50.0%
|
$8,000,000
$16.0 P/Share
|
|
Jun 01
2021
|
Atlas Venture Fund Xi, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
8,502,776
+50.0%
|
-
|
|
Jun 01
2021
|
Papanek Julie Grant Director |
BUY
Open market or private purchase
|
Indirect |
13,000
+0.12%
|
$208,000
$16.0 P/Share
|
|
Jun 01
2021
|
Papanek Julie Grant Director |
BUY
Conversion of derivative security
|
Indirect |
7,476,776
+21.15%
|
-
|
|
Jun 01
2021
|
Daniel J. Becker Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$80,000
$16.0 P/Share
|
|
Jun 01
2021
|
John A. Josey |
BUY
Open market or private purchase
|
Direct |
7,000
+8.83%
|
$112,000
$16.0 P/Share
|